[go: up one dir, main page]

WO2008030367A3 - Selective myostatin inhibitors - Google Patents

Selective myostatin inhibitors Download PDF

Info

Publication number
WO2008030367A3
WO2008030367A3 PCT/US2007/018974 US2007018974W WO2008030367A3 WO 2008030367 A3 WO2008030367 A3 WO 2008030367A3 US 2007018974 W US2007018974 W US 2007018974W WO 2008030367 A3 WO2008030367 A3 WO 2008030367A3
Authority
WO
WIPO (PCT)
Prior art keywords
myostatin inhibitors
selective
selective myostatin
inhibitors
follistatins
Prior art date
Application number
PCT/US2007/018974
Other languages
French (fr)
Other versions
WO2008030367A2 (en
Inventor
Philip A Krasney
Alan Schneyer
Original Assignee
Gen Hospital Corp
Pfizer Prod Inc
Philip A Krasney
Alan Schneyer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gen Hospital Corp, Pfizer Prod Inc, Philip A Krasney, Alan Schneyer filed Critical Gen Hospital Corp
Publication of WO2008030367A2 publication Critical patent/WO2008030367A2/en
Publication of WO2008030367A3 publication Critical patent/WO2008030367A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Provided are mutant follistatins that act as selective myostatin inhibitors, as well as methods of using the same to treat muscle wasting disorders.
PCT/US2007/018974 2006-09-01 2007-08-29 Selective myostatin inhibitors WO2008030367A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US84184106P 2006-09-01 2006-09-01
US60/841,841 2006-09-01

Publications (2)

Publication Number Publication Date
WO2008030367A2 WO2008030367A2 (en) 2008-03-13
WO2008030367A3 true WO2008030367A3 (en) 2008-10-16

Family

ID=39157757

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/018974 WO2008030367A2 (en) 2006-09-01 2007-08-29 Selective myostatin inhibitors

Country Status (1)

Country Link
WO (1) WO2008030367A2 (en)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8128933B2 (en) 2005-11-23 2012-03-06 Acceleron Pharma, Inc. Method of promoting bone growth by an anti-activin B antibody
TWI432449B (en) 2007-02-02 2014-04-01 Acceleron Pharma Inc Variants derived from ActRIIB and their uses
CN107252486B (en) 2008-06-26 2021-10-22 阿塞勒隆制药公司 Antagonists of activin-ACTRII and uses in increasing red blood cell levels
AU2009262970A1 (en) 2008-06-26 2009-12-30 Acceleron Pharma Inc. Methods for dosing an activin-ActRIIa antagonist and monitoring of treated patients
US8216997B2 (en) 2008-08-14 2012-07-10 Acceleron Pharma, Inc. Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators
AU2010292203A1 (en) 2009-09-09 2012-04-12 Acceleron Pharma Inc. ActRIIb antagonists and dosing and uses thereof
EP3608419B1 (en) 2012-10-24 2025-03-26 Celgene Corporation Biomarker for use in treating anemia
NZ707477A (en) 2012-11-02 2019-09-27 Celgene Corp Activin-actrii antagonists and uses for treating bone and other disorders
KR102253597B1 (en) 2013-01-25 2021-05-17 샤이어 휴먼 지네틱 테라피즈 인크. Follistatin in treating duchenne muscular dystrophy
AU2015247459A1 (en) 2014-04-18 2016-10-27 Acceleron Pharma, Inc. Methods for increasing red blood cell levels and treating sickle-cell disease
US10010498B2 (en) 2014-06-04 2018-07-03 Acceleron Pharma Inc. Methods for treatment of amyotrophic lateral sclerosis with follistatin fusion proteins
EA035455B1 (en) 2014-06-04 2020-06-18 Акселерон Фарма, Инк. Methods and compositions for treatment of disorders with follistatin polypeptides
BR122023023170A2 (en) 2014-06-13 2024-02-20 Acceleron Pharma Inc. USE OF AN ACTRII ANTAGONIST IN THE TREATMENT OR PREVENTION OF SKIN ULCERS ASSOCIATED WITH BETA-THALASSEMIA
MA41052A (en) 2014-10-09 2017-08-15 Celgene Corp TREATMENT OF CARDIOVASCULAR DISEASE USING ACTRII LIGAND TRAPS
MA41119A (en) 2014-12-03 2017-10-10 Acceleron Pharma Inc METHODS OF TREATMENT OF MYELODYSPLASIC SYNDROMES AND SIDEROBLASTIC ANEMIA
SMT202300166T1 (en) 2014-12-03 2023-07-20 Celgene Corp Activin-actrii antagonists and uses for treating myelodysplastic syndrome
JP2018510637A (en) 2015-03-26 2018-04-19 アクセルロン ファーマ， インコーポレイテッド Follistatin-related fusion protein and use thereof
MA41919A (en) 2015-04-06 2018-02-13 Acceleron Pharma Inc ALK4 HETEROMULTIMERS: ACTRIIB AND THEIR USES
KR20180002661A (en) 2015-04-06 2018-01-08 악셀레론 파마 인코포레이티드 ALK7: ActRIIB heteropolymers and their uses
EP3370754A4 (en) 2015-11-04 2019-10-23 Acceleron Pharma Inc. METHODS FOR INCREASING ERYTHROCYTE RATES AND TREATING INEFFECTIVE ERYTHROPOISIS
AU2016359695A1 (en) 2015-11-23 2018-06-14 Acceleron Pharma Inc. Methods for treating eye disorders
SG11201807400TA (en) * 2016-03-04 2018-09-27 Shire Human Genetic Therapies Recombinant follistatin-fc fusion proteins and use in treating duchenne muscular dystrophy
EP3439741A4 (en) 2016-04-06 2020-05-06 Acceleron Pharma Inc. ALK7 ANTAGONISTS AND USES THEREOF
MY199499A (en) * 2016-06-13 2023-11-01 Scholar Rock Inc Use of myostatin inhibitors and combination therapies
RU2748278C2 (en) 2016-07-15 2021-05-21 Акселерон Фарма Инк. Compositions and methods of pulmonary hypertension treatment
MA45811A (en) 2016-07-27 2019-06-05 Acceleron Pharma Inc METHODS AND COMPOSITIONS OF TREATMENT OF DISEASE.
US11976111B2 (en) 2016-10-05 2024-05-07 Acceleron Pharma Inc. ActRIIa and ALK4 polypeptides for treating kidney fibrosis, inflammation and injury
WO2019046903A1 (en) * 2017-09-08 2019-03-14 Baker Heart and Diabetes Institute A therapeutic method of increasing muscle mass in a subject
US20220380422A1 (en) * 2021-05-28 2022-12-01 Lirsamax, Inc. Method for treating muscle atrophy and/or obesity and composition for use in said method
IL321628A (en) 2022-12-22 2025-08-01 Scholar Rock Inc Selective and potent inhibitory antibodies of myostatin activation

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005100563A1 (en) * 2004-04-15 2005-10-27 Techno Network Shikoku Co., Ltd. Follistatin mutant polypeptide
US20070135336A1 (en) * 2003-09-15 2007-06-14 De Kretser David Follistatin isoforms and uses thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070135336A1 (en) * 2003-09-15 2007-06-14 De Kretser David Follistatin isoforms and uses thereof
WO2005100563A1 (en) * 2004-04-15 2005-10-27 Techno Network Shikoku Co., Ltd. Follistatin mutant polypeptide

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
SIDIS ET AL.: "Biological Activity of Follistatin Isoforms and Follistatin-Like-3 Is Dependent on Differential Cell Surface Binding and Specificity for Activin, Myostatin, and Bone Morphogenetic Proteins.", ENDOCRINOLOGY, vol. 147, 2006, pages 3586 - 3597 *
TSUCHIDA K.: "Activins, Myostatin and Related TGF-R Family Members as Novel Therapeutic Targets for Endocrine, Metabolic and Immune Disorders.", CURRENT DRUG TARGETS - IMMUNE, ENDOCRINE & METABOLIC DISORDERS, vol. 4, 2004, pages 157 - 166 *

Also Published As

Publication number Publication date
WO2008030367A2 (en) 2008-03-13

Similar Documents

Publication Publication Date Title
WO2008030367A3 (en) Selective myostatin inhibitors
WO2007146965A3 (en) Compounds for the treatment of periodontal disease
WO2009129246A3 (en) Compositions and methods for preparing and using same
WO2008128072A3 (en) Axl kinase inhibitors useful for the treatment of cancer or hyperproliferative disorders
EP2023926A4 (en) Pyridonecarboxamide derivatives useful in treating hyper-proliferative and angiogenesis disorders
IL193080A0 (en) Methods, compositions, and kits for the treatment of musculoskeletal disorders and symptoms associated therewith
PL1993985T3 (en) Process for the preparation of 1,2-propanediol
WO2010077740A3 (en) Novel antiviral compounds, compositions, and methods of use
WO2008095086A3 (en) Topiramate plus naltrexone for the treatment of addictive disorders
WO2009042114A3 (en) Phenazine derivatives and uses thereof
UA99936C2 (en) Biaryl substituted azabicyclic alkane derivatives
WO2006015159A3 (en) Potassium channel inhibitors
WO2007133622A3 (en) Selective inhibitors of rock protein kinase and uses thereof
WO2010004197A3 (en) Pyridino-pyridinone derivatives, preparation thereof, and therapeutic use thereof
WO2009085270A3 (en) Use of inhibitors of c0nnexin43 for treatment of fibrotic conditions
WO2010071783A8 (en) Thiazoles as cannabinoid receptor ligands
WO2009158719A3 (en) Methods and compositions for treating disorders
SI2229369T1 (en) 6,7-dialkoxy-quinazoline derivatives useful for treatment of cancer-related disorders
IL190730A0 (en) Potassium channel inhibitors
WO2008027600A3 (en) Imatinib compositions
WO2007050348A3 (en) Potassium channel inhibitors
WO2010030891A3 (en) Aryl guanidine f1f0-atpase inhibitors and related methods
WO2007122382A3 (en) Lycopene for the treatment of metabolic dysfunction
WO2007136741A3 (en) N-desmethyl-doxepin and methods of using the same to treat sleep disorders
GB2465814B (en) Method,composition and device for the treatment of enzymes and saccharides disorders

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07837462

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07837462

Country of ref document: EP

Kind code of ref document: A2